文献速递血液透析通路

头静脉转位与移植物间置术后发生狭窄的血管内治疗效果

Outcomes of endovascular treatment for stenosis occurring after cephalic vein transposition and graft interposition.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2022-01-21

回顾性分析2017年1月1日至2019年12月31日因头静脉弓狭窄行头静脉转位或移植物间置术后再狭窄的73例患者,比较血管内治疗后的通畅率。血管内治疗后6个月和12个月一期通畅率分别为56.7%和15.6%,二期通畅率分别为89.7%和72.1%。头静脉转位组二期通畅率高于移植物间置组(P=.034),移植物间置是二期通畅率降低的唯一不良因素(HR 3.14,95%CI 1.06-9.34,P<.05)。

要点

  • 血管内治疗是头静脉弓狭窄外科术后再狭窄的可接受选择。
  • 头静脉转位组二期通畅率高于移植物间置组(P=.034)。
  • 移植物间置是二期通畅率降低的唯一不良因素(HR 3.14,95%CI 1.06-9.34,P<.05)。

核心结论

  • 血管内治疗仍是头静脉弓狭窄外科治疗后发生狭窄的可接受选择。
  • 头静脉转位相比移植物间置提供更高的干预后二期通畅率。

研究设计与样本

  • 回顾性综述2017年1月1日至2019年12月31日因头静脉弓狭窄行头静脉转位或移植物间置术后再狭窄并接受血管内治疗的73例患者。
  • 患者分为头静脉转位组(BCF-CVT,n=49)和移植物间置组(BCF-GIP,n=24)。
  • 采用Kaplan-Meier分析计算干预后一期和二期通畅率,并分析与干预后通畅率丧失相关的变量。

主要发现

  • 血管内治疗再狭窄后6个月和12个月一期通畅率分别为56.7%和15.6%,二期通畅率分别为89.7%和72.1%。
  • BCF-CVT组6个月和12个月一期通畅率分别为56.8%和17.6%,二期通畅率分别为93.3%和79.4%。
  • BCF-GIP组6个月和12个月一期通畅率分别为56.5%和8.7%,二期通畅率分别为85.7%和56.3%。
  • 两组干预后一期通畅率无显著差异(P=.79),BCF-CVT组干预后二期通畅率更高(P=.034)。
  • BCF-GIP组狭窄部位数量更多(P<.01),且是干预后二期通畅率降低的唯一不良变量(HR 3.14,95%CI 1.06-9.34,P<.05)。

临床怎么用

  • 原文结论认为血管内治疗仍是头静脉弓狭窄外科治疗后发生狭窄的可接受选择。
  • 原文结论认为头静脉转位相比移植物间置提供更高的干预后二期通畅率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the outcome of endovascular treatment after surgical treatment for cephalic arch stenosis (CAS) in the brachiocephalic fistula (BCF) and to analyze the factors influencing patency. METHODS: We conducted a retrospective review of patients undergoing cephalic vein transposition (CVT) or graft interposition (GIP) for CAS from January 1, 2017, to December 31, 2019. A total of 73 patients with restenosis were included in this study. Patients were classified into cephalic transposition (BCF-CVT) (n = 49) and graft interposition (BCF-GIP) (n = 24) groups. We calculated the postintervention primary and secondary patency of endovascular treatment by using the Kaplan-Meier analysis and analyzed variables associated with loss of postintervention patency. RESULTS: Six-month and 12-month postintervention primary patency rates of endovascular treatment for restenosis were 56.7% and 15.6% and secondary patency rates were 89.7% and 72.1%, respectively. In the BCF-CVT group, 6-month and 12-month postintervention primary patency was 56.8% and 17.6% and secondary patency was 93.3% and 79.4%, respectively. In the BCF-GIP group, 6-month and 12-month postintervention primary patency was 56.5% and 8.7% and secondary patency was 85.7% and 56.3%, respectively. There was no significant difference in postintervention primary patency between the two groups (P = .79). However, the BCF-CVT group demonstrated higher postintervention secondary patency (P = .034). The BCF-GIP group had a higher number of stenosis sites (P < .01). There was no significant predictor of reduced postintervention primary patency. The only adverse variable of postintervention secondary patency was BCF-GIP (hazard ratio, 3.14; 95% CI, 1.06-9.34; P < .05). CONCLUSIONS: Endovascular treatment is still the acceptable option for stenosis occurring after surgical treatment for CAS. CVT provides higher postintervention secondary patency than GIP.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Jeong J, Kim YJ, Goo DE, et al. Outcomes of endovascular treatment for stenosis occurring after cephalic vein transposition and graft interposition. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 35074520. doi:10.1016/j.jvsv.2022.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。